Atézolizumab et bévacizumab – carcinome hépato-cellulaire non résécable en première ligne
- 2 February 2021
- journal article
- editorial
- Published by Elsevier BV in Bulletin du Cancer
- Vol. 108 (2), 139-140
- https://doi.org/10.1016/j.bulcan.2020.11.011
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaThe New England Journal of Medicine, 2020
- Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)Annals of Oncology, 2019
- Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).Journal of Clinical Oncology, 2019
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008